ANDREA-LD: ANti-psychotic Drug REduction in primary care for Adults with Learning Disabilities (ANDREA-LD): a randomised double-blind placebo-controlled trial

Cardiff University (UK)0 个研究点目标入组 310 人开始时间: 2013年4月8日最近更新: 2018年8月27日

适应症

试验速览

•1. Aged 18 or over
•2. Have a learning disability as judged by administrative classification (e.g. on practice learning disability register, in receipt of an annual learning disability health check, in receipt of learning disability services) and a score on the Adaptive Behaviour Scale that converts to an estimated IQ of 70 or below using the method described by Moss and Hogg
•3. Currently prescribed one of two anti-psychotic drugs, haloperidol or risperidone, for treatment of challenging behaviour

•1. Current diagnosis of psychosis
•2. Known recurrence of psychosis following previous drug reduction in the past 3 years
•3. The clinician responsible for their treatment judges for any other reason that the participation in a drug reduction programme may be counter-indicated.

发起方

Cardiff University (UK)